Clinical Trials Logo

Toxicity Due to Chemotherapy clinical trials

View clinical trials related to Toxicity Due to Chemotherapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06274268 Not yet recruiting - Sarcopenia Clinical Trials

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

SARC-ONCO
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

NCT ID: NCT05885048 Not yet recruiting - Cancer Clinical Trials

Impact of Gonadotoxic Therapies on Fertility

FertiTOX
Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: - in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); - in males, if cancer therapies reduce sperm concentration (sperm quality).

NCT ID: NCT02934971 Not yet recruiting - Clinical trials for Toxicity Due to Chemotherapy

Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy to Predict Arising Heart Failure

MERMAID
Start date: January 2017
Phase: N/A
Study type: Observational

The present project will develop an automated machine learning approach using multi-modality data (imaging, laboratory, electrocardiography and questionnaire) to increase the understanding and prediction of arising heart failure in patients scheduled for cardio-toxic chemotherapy. This algorithmus will be developed by the technical cooperation partner at Technion, the institut for biomedical engineering in Haifa, Israel.